A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is
 safe and effective. The study lasts approximately 20 weeks.
This will be a multi-center, double-blind, placebo controlled, parallel, 12 week treatment
 trial in men with signs and symptoms of benign prostatic hyperplasia. The following
 procedures are utilized: physical exams, electrocardiograms, clinical laboratory tests, vital
 signs, the International Prostate Symptom Score, maximum urine flow rate, pharmacokinetics,
 adverse events, concomitant medications, quality of life, and compliance.
Inclusion Criteria:

 -  Males in good general health and at least 50 years of age, with symptoms of moderate
 to severe benign prostatic hyperplasia.

 Exclusion Criteria:

 -  Medical conditions that would confound the efficacy evaluation.

 -  Medical conditions in which it would be unsafe to use an alpha-blocker.

 -  The use of concomitant drugs that would confound the efficacy evaluation.

 -  The use of concomitant drugs that would be unsafe with this alpha-blocker.